A randomized, Double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients

American Journal of Transplantation

Volumn 9, Issue 10, 2009, Pages 2324-2330

  Pescovitz, M D ^a   Bloom, R ^b   Pirsch, J ^c   Johnson, J ^d   Gelone, S ^d   Villano, S A ^d  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d ViroPharma Incorporated   (United States)

Author keywords

Cytomegalovirus (CMV); Drug development; Drug interaction; Drug metabolism; Pharmacokinetics; Tacrolimus; Transplant infectious diseases; Viral; Viral therapy

Indexed keywords

BENZIMIDAVIR; PLACEBO; TACROLIMUS;

ADULT; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG MONITORING; DYSGEUSIA; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLACEBOS; RIBONUCLEOSIDES; TACROLIMUS;

EID: 70349202876     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02768.x     Document Type: Article

References (13)

1. Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995 60 : 225 232.
2. Maribavir: 1263W94, Benzimidavir, GW 1263, GW 1263W94, VP 41263. Drugs R D 2007 8 : 188 192.
3. Pescovitz MD. Maribavir: A new oral anti-cytomegalovirus drug. Future Virology 2008 3 : 435 443.
4. Biron KK, Harvey RJ, Chamberlain SC et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob Agents Chemother 2002 46 : 2365 2372.
5. Drew WL, Miner RC, Marousek GI, Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006 37 : 124 127.
6. McSharry JJ, McDonough A, Olson B, Talarico C, Davis M, Biron KK. Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole l-riboside 1263W94. Clin Diagn Lab Immunol 2001 8 : 1279 1281.
7. Wiltshire H, Hirankarn S, Farrell C et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005 44 : 495 507.
8. Wiltshire H, Paya CV, Pescovitz MD et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005 79 : 1477 1483.
9. Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2003 47 : 1334 1342.
10. Swan SK, Smith WB, Marbury TC et al. Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment. J Clin Pharmacol 2007 47 : 209 217.
11. Ma JD, Nafziger AN, Villano SA, Gaedigk A, Bertino JS Jr. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother 2006 50 : 1130 1135.
12. Downey R, Johnson J, Gelone S, Broom C, Villano S. Lack of a pharmacokinetic (PK) interaction between oral Maribavir, a novel anti-cytomegalovirus agent and the CYP 2C19 substrate Voriconazole, in healthy volunteers. 110th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2009 National Harbor, MD Poster PIII-74.
13. Goldwater DR, Dougherty C, Schumacher M, Villano SA. Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults. Antimicrob Agents Chemother 2008 52 : 1794 1798.